Inactive Instrument

News Summit Therapeutics plc London S.E.

Equities

GB00BN40HZ01

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024	May. 01
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024	May. 01	BU
Summit Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024	Apr. 24	BU
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors	Apr. 11	BU
Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors	Apr. 11	CI
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum	Apr. 10	BU
Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed	Apr. 09	RE
Illumina Names Ankur Dhingra as Chief Financial Officer	Apr. 09	MT
Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor	Apr. 09	RE
Summit Therapeutics Appoints COO to Additional Role of CFO	Apr. 04	MT
Summit Therapeutics Inc. Announces Chief Financial Officer Changes	Apr. 03	CI
Summit Therapeutics Inc. Appoints Bhaskar Anand as Chief Accounting Officer, Head of Finance, to Serve as Its Principal Accounting Officer	Apr. 03	CI
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	Apr. 01	MT
Summit Therapeutics Insider Bought Shares Worth $375,000, According to a Recent SEC Filing	Mar. 28	MT
Stifel Initiates Summit Therapeutics With Buy Rating, $8 Price Target	Mar. 26	MT
Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	Mar. 25	AQ
Summit Therapeutics Reports 23% Complete Response in Metastatic NSCL Cancer Drug Ivonescimab's Clinical Trials	Mar. 22	MT
Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	Mar. 22	BU
Summit Therapeutics Inc. Announces Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	Mar. 22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Summit Therapeutics plc London S.E.

Equities

GB00BN40HZ01

Summary

Filters